Armstrong, A. W.; Lebwohl, M.; Bagel, J.; Schlesinger, T.; Banerjee, S.; Kisa, R. M.; Scharnitz, T.; Hoyt, K.; Strober, B. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). J of Skin 2023, 7, s120.